Chudova Darya sold $1.4M of GH

Chudova Darya (Chief Technology Officer) sold 7,738 shares of Guardant Health, Inc. (GH) at $178.00 ($1.38M total) on 2026-09-15.

Original reporting
SEC EDGAR · Chudova Darya
Published Sep 17, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Bearish
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBearishLow
01

Why it matters

The sale reduces insider ownership, which can be interpreted as a slight bearish signal.

02

Market read

First-report insider sale provides new data for traders assessing short-term sentiment.

03

What to watch

Potential upcoming stock dilution or financing activities could be a factor.

Relevance 6/10Novelty 7/10Timing: filed Sep 17 after market close

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$GHBearishMedium confidence
Context

Chief Technology Officer sold 7,738 shares for $1.38M, reducing her stake to 70,635 shares.

Expected impact

Potential modest dip in near-term price.

Evidence & confidence

Sale size is notable for a C-level exec, but not large enough to suggest major concerns.

Market effects

Minimal impact on biotech sector; insider sales are common.

None

Low

Counterpoint

Insider may be diversifying; sale does not necessarily reflect company outlook.

Key entities

  • Guardant Health, Inc.

    US-listed biotech firm (ticker GH).

  • Chudova Darya

    Chief Technology Officer of Guardant Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.